CDXS

Business Context and Reporting Period

Company: Codexis, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Overview: Codexis develops proprietary biocatalysts (enzymes and microbes) for the pharmaceutical and biofuels industries. The company operates primarily through collaborative research and development (R&D) agreements, product sales, and government grants. A significant portion of revenue is derived from a multi-year collaboration with Shell Oil Products US for biofuels development.

Key Financial Metrics

Revenue Composition (Q1 2010):

• Related Party Collaborative R&D (Shell): $16,042 (62% of total)
• Product Revenues: $6,275 (24% of total)
• Government Grants: $2,722 (11% of total)
• Other Collaborative R&D: $661 (3% of total)

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 32% year-over-year, driven by a $2.7 million government grant from the Singapore Economic Development Board, a $1.4 million milestone payment from Shell, and increased product sales.
• Profitability Improvement: Net loss narrowed significantly from $6.1 million to $1.4 million. This was primarily due to a $3.0 million reduction in royalty fees paid to Maxygen (a related party) compared to the prior year.
• Operating Expenses: Research and Development (R&D) expenses decreased 14% to $13.0 million, while Selling, General, and Administrative (SG&A) expenses increased 42% to $8.6 million due to higher headcount and stock-based compensation.
• Liquidity: Cash and cash equivalents decreased by $2.6 million during the quarter. Net cash used in operating activities increased to $12.0 million, largely due to changes in working capital (specifically a decrease in deferred revenues).

Outlook, Risks, and Unusual Items

• Profitability Outlook: Management does not expect to achieve profitability prior to at least 2011 due to continued heavy investment in R&D and infrastructure.
• Subsequent Event (IPO): On April 27, 2010, the company completed its Initial Public Offering (IPO), selling 6 million shares at $13.00 per share for net proceeds of approximately $68.0 million. This event occurred after the reporting period and is not reflected in the financial statements.
• Key Risks:
  • Customer Concentration: Shell accounted for 62% of total revenues in Q1 2010. The top five customers accounted for 87% of revenues.
  • Intellectual Property: The company relies heavily on technology licensed from Maxygen. Loss of these rights or failure to pay royalties could materially harm operations.
  • Internal Controls: The company identified a significant deficiency in its contract compliance process as of December 31, 2009, which it is actively remediating.
  • Biofuels Market: Success in the biofuels sector depends on Shell's commercialization efforts and the feasibility of cellulosic ethanol production.
• Unusual Items: The quarter included a $2.7 million government grant revenue which was not present in the comparable prior period. Additionally, $0.2 million in inventory write-downs were recorded in cost of product revenues.

Investor Verification Checklist

• Shell Collaboration Status: Verify the stability of the Shell agreement, specifically regarding the number of funded Full-Time Equivalents (FTEs) and potential for reduction after November 2010.
• Maxygen Royalty Obligations: Confirm the terms of the license agreement with Maxygen and the impact of future Shell payments on royalty expenses.
• Deferred Revenue Recognition: Review the timing of revenue recognition for collaborative agreements, as a significant portion of revenue is deferred and recognized over time.
• Internal Control Remediation: Assess the progress of remediation efforts regarding the identified significant deficiency in contract compliance.
• Post-IPO Liquidity: Confirm the utilization of the $68 million IPO proceeds and the company's runway for operations given the history of negative operating cash flow.